These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 1367141)
1. Fungi as bioprocessing systems for the production of pharmaceutically important proteins. Gwynne DI; Smart NJ Bioprocess Technol; 1991; 13():391-401. PubMed ID: 1367141 [No Abstract] [Full Text] [Related]
2. [Recent advances in the production of heterologous proteins in filamentous fungi]. Zhong Y; Wang X; Wang T Sheng Wu Gong Cheng Xue Bao; 2008 Apr; 24(4):531-40. PubMed ID: 18616158 [TBL] [Abstract][Full Text] [Related]
3. Sandoz sues FDA over delay in first biogeneric approval. Fox JL Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046 [No Abstract] [Full Text] [Related]
4. Approval times for supplemental indications for recombinant proteins. Gosse ME; Nelson TF Nat Biotechnol; 1997 Feb; 15(2):130-4. PubMed ID: 9035135 [No Abstract] [Full Text] [Related]
5. Recombinant expression systems in the pharmaceutical industry. Schmidt FR Appl Microbiol Biotechnol; 2004 Sep; 65(4):363-72. PubMed ID: 15480623 [TBL] [Abstract][Full Text] [Related]
6. Heterologous protein production by filamentous fungi. Jeenes DJ; Mackenzie DA; Roberts IN; Archer DB Biotechnol Genet Eng Rev; 1991; 9():327-67. PubMed ID: 1839127 [TBL] [Abstract][Full Text] [Related]
7. Regulatory evaluation of biotechnology drugs: current trends in the United States. Sobel S Bioprocess Technol; 1991; 13():499-511. PubMed ID: 1367148 [No Abstract] [Full Text] [Related]
12. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents. Teitelbaum R; Cohen M Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990 [No Abstract] [Full Text] [Related]
13. Biotech patents-business as usual? Lawrence S Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861 [No Abstract] [Full Text] [Related]
14. Production and analysis of proteins by recombinant DNA technology. Pestka S Bioprocess Technol; 1990; 7():235-65. PubMed ID: 1366823 [No Abstract] [Full Text] [Related]
15. Increased production of chymosin by glycosylation. van den Brink HJ; Petersen SG; Rahbek-Nielsen H; Hellmuth K; Harboe M J Biotechnol; 2006 Sep; 125(2):304-10. PubMed ID: 16621086 [TBL] [Abstract][Full Text] [Related]
16. Recent developments help the defense of drug companies in 10b-5 cases. Salpeter AN; Hutchins H Food Drug Law J; 1996; 51(3):345-53. PubMed ID: 11797711 [No Abstract] [Full Text] [Related]
17. Beyond the letter of the law: the US Federal Circuit interprets section 271(g)(1). Tsao R; Hurley EA Nat Biotechnol; 1997 Jan; 15(1):86-7. PubMed ID: 9035112 [No Abstract] [Full Text] [Related]
18. Production of medically important proteins. Palva I Ann Clin Res; 1986; 18(5-6):337-43. PubMed ID: 3551778 [No Abstract] [Full Text] [Related]
19. Transfection and transformation of human and animal cells by recombinant DNA vectors: issues relevant to use of these substrates for the production of biologicals. Moyer MP; Moyer RC Dev Biol Stand; 1989; 70():91-100. PubMed ID: 2547678 [TBL] [Abstract][Full Text] [Related]
20. The application of the patent laws to the drug approval process. Coggio BD; Cerrito FD Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669 [No Abstract] [Full Text] [Related] [Next] [New Search]